Drug Trial Radar · NCT03711604
Compassionate Use Study of Tenalisib (RP6530)
Last checked: Nov 19, 2026Latest source record: May 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
17
Actual
Start
Nov 28, 2018
Primary completion
Mar 25, 2023
Study completion Mar 25, 2023
Sponsor
- Lead sponsor
- Rhizen Pharmaceuticals SAIndustry
- Sponsor type
- Industry
- First posted
- Oct 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Tenalisib has been evaluated as an investigational new drug in number of early clinical studies in patients with relapsed/refractory hematological malignancies and demonstrated acceptable safety and promising efficacy in these patients. Since these advanced relapsed/refractory patients have limited therapeutic options, it is reasonable to continue Tenalisib in responding patients post completion of their participation in previous clinical studies.
Conditions
- Hematological Malignancies
Interventions
TenalisibDrug
BID Orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Treatment-related Adverse EventsTime frame: 2 years
- Time to Disease ProgressionTime frame: 2 years
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
University of California, Hellen Diller Family Comprehensive Cancer Center
San Francisco, California
Division of Hematology, University of Colorado,
Denver, Colorado
Cleveland Clinic Taussig Cancer Institute
Cleveland, Ohio
The University of Texas MD Anderson Cancer Center
Houston, Texas
Ltd. M.Zodelava Hematology Centre
Tbilisi, Georgia
Medivest - Institute of Hematology and Transfusiology
Tbilisi, Georgia
Silesian Healthy Blood Clinic Grosicki, Grosicka Sp.J.
Chorzów, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.